6533b873fe1ef96bd12d531d

RESEARCH PRODUCT

Sufentanil sublingual tablet system. From rationale of use to clinical practice

Vergari ACortegiani ARispoli MColuzzi FDeni FLeykin YLuca Lorini FMartorano P PPaolicchi APolati EScardino MCorcione AGiarratano ARossi M

subject

Pain PostoperativeAdministration SublingualAnalgesia Patient-ControlledClinical practiceNeuropathic painAcute PainSSTAnalgesics OpioidSSTSsufentanilclinical practice; neuropathic pain; SSTS; surgeryPractice Guidelines as TopicHumansPain ManagementSurgeryTablets

description

The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.

yearjournalcountryeditionlanguage
2020-12-04
10.26355/eurrev_202011_23847http://hdl.handle.net/11573/1479871